Lucid Diagnostics (LUCD) Net Income towards Common Stockholders (2020 - 2026)
Lucid Diagnostics' (LUCD) quarterly Net Income towards Common Stockholders came in at -$23.6 million in Q1 2026, up 34.48% YoY from -$17.5 million in Q1 2025, and down 44.79% on a QoQ basis from -$16.3 million in Q4 2025.
Lucid Diagnostics (LUCD) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Lucid Diagnostics (LUCD) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$23.6 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 34.48% year-over-year to -$23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.2 million (up 17.97% YoY) and the FY2025 annual result came in at -$70.6 million, down 33.14% from the prior year.
- Net Income towards Common Stockholders fell to -$23.6 million in Q1 2026, from -$16.3 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$7.9 million in Q2 2025 to a low of -$36.0 million in Q1 2025.
- A 5-year average of -$15.1 million and a median of -$14.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 235.89% — and 2026, when it jumped 34.48%.
- Tracing LUCD's Net Income towards Common Stockholders over 5 years: stood at -$14.9 million in 2022, then rose by 27.45% to -$10.8 million in 2023, then decreased by 6.57% to -$11.5 million in 2024, then slumped by 41.24% to -$16.3 million in 2025, then tumbled by 44.79% to -$23.6 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$23.6 million (Q1 2026), -$16.3 million (Q4 2025), and -$10.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Lucid Diagnostics | 176.00 Mn | 142.60 Mn | 55,000.00 | -14.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.72 Mn |
| Mar 31, 2026 | -23.60 Mn |
| Dec 31, 2025 | -16.30 Mn |
| Sep 30, 2025 | -10.40 Mn |
| Jun 30, 2025 | -7.89 Mn |
| Mar 31, 2025 | -36.02 Mn |
| Dec 31, 2024 | -11.54 Mn |
| Sep 30, 2024 | -12.37 Mn |
| Jun 30, 2024 | -11.01 Mn |
| Mar 31, 2024 | -18.11 Mn |
| Dec 31, 2023 | -10.83 Mn |
| Sep 30, 2023 | -14.21 Mn |
| Jun 30, 2023 | -11.38 Mn |
| Mar 31, 2023 | -16.25 Mn |
| Dec 31, 2022 | -14.93 Mn |
| Sep 30, 2022 | -14.35 Mn |
| Jun 30, 2022 | -14.62 Mn |
| Mar 31, 2022 | -12.27 Mn |
| Dec 31, 2021 | -11.31 Mn |
| Sep 30, 2021 | -6.96 Mn |